Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure

Amrousy, Doaa El; Hodeib, Hossam; Suliman, Ghada Abdulmomen; Hablas, Nahed Mohammed; Salama, Eman Ramadan; Esam, Ahmed

doi:10.1007/s00246-016-1532-2

Cited by 14 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exact release mechanism of cMyBP-C in heart failure is still unknown. Moreover, cMyBP-C has a 90% sensitivity and 93% specificity as a biomarker of prognosis in heart failure patient at cutoff value of 152 ng/ml [48]. The same study showed that failure to decrease the level of serum cMyBP-C leads to poor prognosis.…”

Section: Cmybp-c As Biomarker For Dcm and Heart Failurementioning

confidence: 84%

“…Dilated Cardiomyopathy is a common cause of heart failure, affecting the heart musculature and vasculature and involves one or several underlying pathophysiological mechanisms [47]. Myocyte injury can lead to DCM and causes release of related biomarkers including that of cMyBP-C. At cutoff value of 45 ng/ml, serum cMyBP-C turns out to have 100% sensitivity and 96% specificity as diagnostic biomarker for heart failure [48]. The exact release mechanism of cMyBP-C in heart failure is still unknown.…”

Section: Cmybp-c As Biomarker For Dcm and Heart Failurementioning

confidence: 99%

See 1 more Smart Citation

Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions

Sun¹,

Dookhun²,

Zou³

et al. 2018

WJCD

View full text Add to dashboard Cite

Since its discovery, myosin-binding protein C (cMyBP-C) has become a protein of interest clinically. With emergence of new methodologies and technologies, the structure and functions of cMyBP-C from different aspects can be studied, enabling us to better understand its involvement in certain cardiac conditions. Studying its kinetics of release and clearance from the circulation and by comparing to other conventional biomarkers, it has been reported that cMyBP-C is eligible to be a novel biomarker for several cardiac conditions. Moreover, studying the genetics and their involvement in pathogenic mechanisms has opened the ideas for potential therapeutic strategies. More and more researches are constantly being done to better understand the role of cMyBP-C in dilated cardiomyopathy (DCM). The importance of cMyBP-C to the heart is still actively being investigated. Its presence is however crucial for sarcomere organization and proper regulation of cardiac contraction during systole and complete relaxation during diastole. Genetic mutation in cMyBP-C has been linked to cardiac conditions including hypertrophic and dilated cardiomyopathies. Around 350 types of mutations have already been documented leading to various cardiac conditions and abnormalities. Analyzing human heart samples has enabled us to better understand the importance of cMyBP-C and how its mutations lead to inherited cardiomyopathies. It is therefore necessary to have an update about the research progress of cMyBP-C in relation to DCM and other cardiac conditions.

show abstract

Section: Cmybp-c As Biomarker For Dcm and Heart Failurementioning

confidence: 84%

Section: Cmybp-c As Biomarker For Dcm and Heart Failurementioning

confidence: 99%

Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions

Sun¹,

Dookhun²,

Zou³

et al. 2018

WJCD

View full text Add to dashboard Cite

show abstract

“…With the use of a cut‐off concentration of 45 ng/mL, the sensitivity reached 100% and its specificity for diagnosing AHF was 96%, while at the cut‐off concentration of 152 ng/mL, its sensitivity and specificity for predicting adverse outcomes were as high as 90% and 93%, respectively. The AUC was 0.999 (95% CI 0.997–1.002) for the diagnosis and 0.915 (95% CI 0.796–1.034) for the prognosis of AHF 30 . However, comparisons between the results of the two studies should be assessed with caution, mainly since the aetiology of AHF in children with a mean age < 2 years in this study substantially differed when compared to the elderly adult AHF population as in our study.…”

Section: Discussionmentioning

confidence: 99%

Cardiac myosin‐binding protein C in the diagnosis and risk stratification of acute heart failure

Kozhuharov

Wussler

Kaier

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

Aims Cardiac myosin‐binding protein C (cMyC) seems to be even more sensitive in the quantification of cardiomyocyte injury vs. high‐sensitivity cardiac troponin, and may therefore have diagnostic and prognostic utility. Methods and results In a prospective multicentre diagnostic study, cMyC, high‐sensitivity cardiac troponin T (hs‐cTnT), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) plasma concentrations were measured in blinded fashion in patients presenting to the emergency department with acute dyspnoea. Two independent cardiologists centrally adjudicated the final diagnosis. Diagnostic accuracy for acute heart failure (AHF) was quantified by the area under the receiver operating characteristic curve (AUC). All‐cause mortality within 360 days was the prognostic endpoint. Among 1083 patients eligible for diagnostic analysis, 51% had AHF. cMyC concentrations at presentation were higher among AHF patients vs. patients with other final diagnoses [72 (interquartile range, IQR 39–156) vs. 22 ng/L (IQR 12–42), P < 0.001)]. cMyC's AUC was high [0.81, 95% confidence interval (CI) 0.78–0.83], higher than hs‐cTnT's (0.79, 95% CI 0.76–0.82, P = 0.081) and lower than NT‐proBNP's (0.91, 95% CI 0.89–0.93, P < 0.001). Among 794 AHF patients eligible for prognostic analysis, 28% died within 360 days; cMyC plasma concentrations above the median indicated increased risk of death (hazard ratio 2.19, 95% CI 1.66–2.89; P < 0.001). cMyC's prognostic accuracy was comparable with NT‐proBNP's and hs‐cTnT's. cMyC did not independently predict all‐cause mortality when used in validated multivariable regression models. In novel multivariable regression models including medication, age, left ventricular ejection fraction, and discharge creatinine, cMyC remained an independent predictor of death and had no interactions with medical therapies at discharge. Conclusion Cardiac myosin‐binding protein C may aid physicians in the rapid triage of patients with suspected AHF.

show abstract

“…Independent of the etiology, neurohormonal activation plays an important role in the pathophysiology of the development and progression of HF [ 2 ]. The renin angiotensin aldosterone system (RAAS) as well as vasopressin (VP) and the sympathetic nervous system are activated in cases of HF leading to salt and water retention, vasoconstriction, and increased heart rate [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Predictive Value of Plasma Copeptin Level in Children with Acute Heart Failure

Amrousy

Nassar

2022

Pediatr Cardiol

View full text Add to dashboard Cite

We investigated the ability of copeptin level to predict adverse outcome in pediatric heart failure (HF) and correlated copeptin level with various clinical and echocardiographic data. This cohort study was carried out on forty children with clinical picture of acute HF as the patient group and forty healthy children of matched age and sex as the control group. Echocardiographic examination and plasma copeptin level were performed for all included children at admission. Patients were followed up for 6 months for mortality or readmission. Plasma copeptin level was significantly higher in the patient group (16.2 ± 5) pmol/L compared to the control group (4.1 ± 2.3) pmol/L, P ˂0.001. Moreover, copeptin level was positively correlated with Ross classification, being the highest in patients with class IV (19.6 ± 3.9) pmol/L compared to those with class III (15.2 ± 4) pmol/L and class II (10.4 ± 1.5) pmol/L. Copeptin levels were significantly higher in patients with bad prognosis (21.2 ± 4.1) pmol/L compared to those with good prognosis (14.5 ± 4.1) pmol/L, P ˂0.001. Copeptin level had a significant positive correlation with age, heart rate, respiratory rate, and ROSS classification. On the contrary, copeptin level had a significant negative correlation with left ventricular fraction shortening and diastolic function. Copeptin at cut-off value of ≥ 19.5 pmol/L yielded a sensitivity of 75% and a specificity of 93% to predict adverse outcome in children with HF. Plasma copeptin level has a good prognostic value to predict adverse outcome in pediatric heart failure. Moreover, copeptin correlate well with the severity of pediatric HF.

show abstract

Diagnostic and Prognostic Value of Plasma Levels of Cardiac Myosin Binding Protein-C as a Novel Biomarker in Heart Failure

Cited by 14 publications

References 14 publications

Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions

Research Progress of Cardiac Myosin Binding Protein C in Dilated Cardiomyopathy and Other Cardiac Conditions

Cardiac myosin‐binding protein C in the diagnosis and risk stratification of acute heart failure

Predictive Value of Plasma Copeptin Level in Children with Acute Heart Failure

Contact Info

Product

Resources

About